Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind, parallel-group comparison, investigators initiated phase II clinical trial of IDEC-C2B8 (Rituximab) in patients with Systemic Sclerosis

Next Previous
Trial Profile

Double-Blind, parallel-group comparison, investigators initiated phase II clinical trial of IDEC-C2B8 (Rituximab) in patients with Systemic Sclerosis

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary)
  • Indications Systemic scleroderma
  • Focus Therapeutic Use
  • Acronyms DesiReS

    • Most Recent Events

    • 15 Feb 2023 Results post hoc analysis evaluating the long-term outcomes after rituximab treatment for SSc and identify potential response markers, published in the JAMA Dermatology
    • 08 Feb 2022 Results of post-hoc analysis (n=54) published in the Rheumatology.
    • 27 Sep 2021 According to a Zenyaku Kogyo media release, the company obtained approval from the Ministry of Health, Labour and Welfare (MHLW), for an anti-CD20 monoclonal antibody, Rituxan injection 100 mg and 500 mg for an additional indication of systemic sclerosis (SSc). Based on findings from this study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top